The legal action, filed in the United States District Court for the Northern District of California, covers individuals who purchased GRAL securities between May 13, 2025, and February 19, 2026. The litigation stems from a sharp decline in share value—$51.32 per share, or roughly 50%—triggered by the disclosure that the NHS-Galleri trial failed to meet its primary endpoint of reducing Stage III and IV cancers.

Joseph E. Levi of Levi & Korsinsky, LLP, noted that the lead plaintiff process allows shareholders with substantial financial interests to oversee litigation strategy. While the appointment does not guarantee a higher individual recovery, it provides direct involvement in the case’s progression. Investors who do not seek this status are not required to take action to remain part of the class, as they retain the right to participate in any eventual settlement or judgment. The firm emphasizes that these securities actions operate on a contingency basis, meaning there are no upfront costs for participating class members.